logo
Menu
Innovation Observatory > Reports > Eye Disease

Results

Drugs

August 2018

Abicipar pegol for wet age related macular degeneration

Abicipar pegol is a novel therapeutic approach that uses a new generation of genetically engineered proteins that exhibit highly specific and high‐affinity target protein binding. As
an anti‐VEGF‐A, it works by inhibiting the growth of immature blood vessels that grow in the retina, reducing the haemorrhaging and scarring that leads to vision impairment. Abicipar
pegol has the potential to require less frequent injections into the eye than the current standard of care, while providing equal improvements in vision. If licensed this could be an effective treatment option with greater compliance for patients with wet age‐related macular degeneration.

Drugs

June 2018

ISV-305 for Ocular Inflammation and Pain Following Cataract Surgery

A cataract is any opacity of the lens, whether it is a small local opacity or a diffuse general loss of transparency. Sometimes, it can cause a significant reduction in visual acuity or a functional impairment. Cataract is the leading cause of blindness in the world. Cataract surgery is currently the only effective treatment to …

Drugs

June 2018

Ranibizumab for Retinopathy of Prematurity – first line

Ranibizumab is a medicinal product already available for treating a range of visual impairments in adult patients. It is injected directly into the eye and it works by preventing abnormal blood vessels from developing and growing in the eye (one of the causes of ROP) by blocking a protein called VEGF. If ranibizumab is licenced for treatment of ROP, it will be the first anti-VEGF medication to be approved for the treatment of ROP. This will potentially provide an alternative treatment to laser and surgical treatments for ROP.

Drugs

November 2017

Lenadogene Nolparvovec (GS-010) for Vision Loss from Leber’s Hereditary Optic Neuropathy Due to Mutation of the ND4 Gene

There are currently very few treatment options for LHON. Most treatment methods are used to support the patient rather than cure them. Lenadogene nolparvovec is a new gene-targeted treatment intended for vision loss caused by LHON due to an alteration in a specific gene. As a genetic medicine, lenadogene nolparvovec could be a promising option …

Drugs

September 2017

Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension

Glaucoma describes a group of disorders characterised by sight loss. Glaucoma is generally associated with high pressure in the liquids inside the eye but it can happen when the pressure level is normal. Individuals with consistently high eye pressure are at risk of developing glaucoma. Glaucoma does not normally cause any symptoms but once eye …

Drugs

April 2017

Brolucizumab (ESBA1008; RTH258) for neovascular age-related macular degeneration (nAMD)

Age-related macular degeneration (AMD) is a major cause of visual impairment in older adults in the UK. It has three stages – early, intermediate, and late – and can occur in one or both eyes. It is possible for one eye to be at the early stage and the other at late stage. There are …

Drugs

November 2016

Dexamethasone intracanalicular insert (Dextenza) for pain and inflammation following cataract surgery

Dexamethasone intracanalicular insert is a new drug that is placed into the canaliculus of the eye to treat pain and inflammation in people who have had cataract surgery. A cataract is when the lens in the eye becomes cloudy causing blurred vision. Cataracts are very common and usually affect older adults. More than 300,000 cataract …

Drugs

September 2016

XG 102 for post-operative inflammation and pain following cataract surgery

XG 102 is a new drug injected into the eye to treat pain and inflammation in people who have had a cataract operation. A cataract occurs when the lens in the eye becomes cloudy causing blurred vision. Cataracts are very common and usually affect those over the age of 65 years. More than 300,000 cataract …

Reviews

September 2016

SUMMARY – New and emerging health technologies for corneal disorders

The NIHR Horizon Scanning Research and Intelligence Centre (HSRIC) has completed a horizon scanning review that identifies new and emerging technologies and procedures for the treatment of corneal disorders. This work was undertaken in response to a question raised by the James Lind Alliance Priority Setting Partnership on Sight Loss and Vision. Corneal disorders may …

Reviews

September 2016

REVIEW – New and emerging health technologies for corneal disorders

The NIHR Horizon Scanning Research and Intelligence Centre (HSRIC) has completed a horizon scanning review that identifies new and emerging technologies and procedures for the treatment of corneal disorders. This work was undertaken in response to a question raised by the James Lind Alliance Priority Setting Partnership on Sight Loss and Vision.   Corneal disorders …

Get Alerts